Receipt of In-Principle Approval for Preferential Issue

APTUS PHARMA LIMITED Date: 30th October 2026 The BSE Ltd Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001 SECURITY CODE: 544529 SCRIPT SYMBOL: APPL Subject: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 – Receipt of In-Principle Approval for Preferential Issue Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that BSE Limited, vide its letter bearing reference no. LOD/PREF/HC/FIP/1040/2026-27 dated October 30, 2026, has granted its in-principle approval under Regulation 28(1) of the SEBI (LODR) Regulations, 2015, for the proposed preferential issue of equity shares of the Company, as approved by the shareholders at their Annual General Meeting held on September 14, 2026. A copy of the in-principle approval letter received from BSE Limited is enclosed herewith for your information and records. Kindly take the above information on record. Thanking you, Yours faithfully, For Aptus Pharma Limited Tejash Hathi Managing Director DIN: 03151221 Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM